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Abstract 42 
Objective: Model trajectories of CD4 and CD8 cell counts after starting combination 43 
antiretroviral therapy (ART), and use the model to predict trends in these counts and the 44 
CD4:CD8 ratio. 45 
Design: Cohort study of antiretroviral-naïve HIV-positive adults who started ART after 1997 46 
(ART Cohort Collaboration) with >6 months of follow-up data. 47 
Methods: We jointly estimated CD4 and CD8 count trends and their correlation using a 48 
bivariate random effects model, with linear splines describing their population trends, and 49 
predicted the CD4:CD8 ratio trend from this model. We assessed whether CD4 and CD8 50 
count trends and the CD4:CD8 ratio trend varied according to CD4 count at start of ART 51 
(baseline), and, whether these trends differed in patients with and without virological failure 52 
more than 6 months after starting ART. 53 
Results: A total of 39,979 patients were included (median follow-up was 53 months). Among 54 
patients with baseline CD4 count ≥50 cells/mm3, predicted mean CD8 counts continued to 55 
decrease between 3 and 15 years post-ART, partly driving increases in the predicted mean 56 
CD4:CD8 ratio. During 15 years of follow-up, normalisation of the predicted mean CD4:CD8 57 
ratio (to >1) was only observed among patients with baseline CD4 count 200 cells/mm3. A 58 
higher baseline CD4 count predicted a shorter time to normalisation. 59 
Conclusions: Declines in CD8 count and increases in CD4:CD8 ratio occurred up to 15 years 60 
after starting ART. The likelihood of normalisation of the CD4:CD8 ratio is strongly related 61 
to baseline CD4 count. 62 
 63 
Keywords: combination antiretroviral therapy, CD4 cell count, CD8 cell count, CD4:CD8 64 
ratio, HIV  65 
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Introduction 66 
Combination antiretroviral therapy (ART) has led to substantial increases in the life-67 
expectancy of HIV-positive individuals [1]. Substantial declines in rates of AIDS have led to 68 
increased interest in non-AIDS, age-related diseases such as cardiovascular diseases, non-69 
AIDS cancers, kidney disease, and neurocognitive decline [2-7], rates of which are higher 70 
than in the general population [8]. HIV infection leads to persistent immune activation and 71 
inflammation, which may accelerate immuno-senescence (deterioration of the immune 72 
system due to ageing) [9]. In the general population, a low CD4:CD8 ratio is a surrogate 73 
marker for immuno-senescence and an independent predictor of all-cause mortality [10,11]. 74 
Among HIV-positive individuals, low CD4:CD8 ratio has been associated with higher levels 75 
of immuno-senescence and inflammation, though the results regarding whether a low or 76 
inverted CD4:CD8 ratio predicts non-AIDS-related morbidity and mortality have been 77 
conflicting [12,13]. 78 
 79 
The benefits of ART for recovery of CD4 cell counts (‘CD4 counts’) are well documented 80 
[14-16]. However, few studies have investigated long-term trends in CD8 cell counts (‘CD8 81 
counts’) [17-21] and in CD4:CD8 ratio [17-24] after starting ART, with almost all based on 82 
small (<150) or moderate (<2000) sample sizes. Given the potential health implications of 83 
elevated CD8 counts and CD4:CD8 ratios below 1 [19,20;25], more information is needed 84 
about their long-term trends in treated patients. 85 
 86 
Our aims were to quantify long-term trends in CD8 counts and CD4:CD8 ratios, up to 15 87 
years after starting ART, in a large cohort of antiretroviral-naïve individuals starting ART, 88 
and assess the impact of baseline CD4 count on these trends. 89 
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 90 
Methods 91 
Study patients 92 
The ART Cohort Collaboration (ART-CC) is an international collaboration between 93 
prospective cohort studies of HIV-positive individuals residing in Europe and North America, 94 
described elsewhere [26] and at www.art-cohort-collaboration.org. Cohorts enrolled HIV-95 
positive ART-naïve individuals aged 16 years starting treatment with a combination of at 96 
least three antiretroviral drugs. All cohorts provided anonymized data on a predefined set of 97 
demographic, laboratory and clinical variables, which were then pooled and analysed 98 
centrally. The NHS Health Research Authority South West, Cornwall and Plymouth 99 
Research Ethics Committee, UK, approved the study (REC reference 12/SW/0253). 100 
 101 
Eligible patients were antiretroviral-naïve, started ART after 1997, had at least one CD4 and 102 
CD8 measurement within the baseline period (defined as 90 days before to 6 days after 103 
starting ART), and one or more CD4 and CD8 measurements 6 months after starting ART.  104 
 105 
Statistical analyses 106 
CD4 and CD8 counts were natural-log transformed (zero counts were set to 1), to stabilize 107 
the variance and meet normality assumptions. When modelling the relationships of 1og-CD4 108 
and 1og-CD8 with time, we considered fractional polynomials of one to four degrees with 109 
powers -2, -1, -0.5, 0, 0.5, 1, 2, 3 (power zero is interpreted as natural-log transformation) and 110 
linear spline models with 2-5 knots. We compared model fit using the Bayesian Information 111 
Criterion (BIC) and the percentage of fitted values within 5% of observed values. We jointly 112 
modelled log-CD4 and log-CD8 using a bivariate random effects model. We included 113 
patient-level random effects for the intercept and trajectory terms, thus allowing trajectories 114 
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to vary between patients. We allowed patient- and measurement-level residuals to be 115 
correlated, thus allowing associations between CD4 and CD8 trajectories at both patient and 116 
measurement levels. Using the best fitting model, we estimated predicted means of 1og-CD4 117 
and 1og-CD8, which when exponentiated became geometric means of CD4 and CD8 counts 118 
respectively. We calculated the difference between predicted means of 1og-CD4 and 1og-119 
CD8, which were exponentiated to derive predicted geometric mean CD4:CD8 ratio. 120 
CD4:CD8 ratios >1 were defined as normalised. 121 
 122 
Patients were classified by their baseline CD4 (<25, 25–49, 50–99, 100–199, 200–349, 350–123 
499, ≥500 cells/mm3), and CD8 (<500, 500–749, 750–999, ≥1000 cells/mm3) counts. Patients 124 
with multiple measurements within the baseline period were classified using the 125 
measurement closest to their ART start date. 126 
 127 
We included covariates sex, age at start of ART, risk transmission group, ethnicity, and 128 
baseline CD4 and CD8 groups. To allow CD4 and CD8 trajectories to vary between baseline 129 
CD4 groups, we included interactions between baseline CD4 group and the intercept and 130 
trajectory terms. 131 
 132 
Virological failure was defined as a HIV RNA measurement exceeding 1000 copies/mL, 133 
regardless of whether a patient had interrupted treatment. We generated a binary, time-134 
independent variable denoting whether, from 6 months after starting ART, patients 135 
experienced at least one virological failure (‘virologically unsuppressed’) or all viral load 136 
measurements were 1000 copies/mL (‘virologically suppressed’). We predicted geometric 137 
means of CD4 and CD8 counts separately among patients classified as virologically 138 
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suppressed and unsuppressed by including three-way interactions between the intercept and 139 
trajectory terms, baseline CD4 group and viral suppression indicator. 140 
 141 
In sensitivity analyses, we predicted geometric mean CD4 and CD8 counts separately among 142 
patients who started treatment before 2004 and from 2004 onwards, and included the 6% of 143 
patients who had no CD4 or CD8 measurements 6 months post-ART. 144 
 145 
Analyses were conducted using STATA/MP version 14 [27], with the runmlwin command 146 
[28] to run software MLwiN (version 3.01) [29] from within Stata. 147 
 148 
Results 149 
Of 110,098 patients included in ART-CC up to 31st December 2013, 15% were excluded 150 
because they started ART before 1998 or before entering the study, 43% without CD4 or 151 
CD8 measurements within the specified baseline period, and 6% because they had no CD4 or 152 
CD8 measurement after 6 months since starting ART. Table 1 presents characteristics of the 153 
remaining 39,979 eligible patients according to baseline CD4 count. Most were men, 154 
approximately 40% were heterosexual, and the median age at start of ART was about 40 155 
years. Higher baseline CD4 count predicted higher baseline CD8 count, with substantial 156 
reductions in median CD8 count as baseline CD4 count decreased from 100-199 cells/mm3 to 157 
<25 cells/mm3. 158 
 159 
Figure 1 shows trajectories of geometric mean CD4 count, CD8 count and CD4:CD8 ratio 160 
according to baseline CD4 group, predicted using the best fitting models (linear splines, with 161 
knots at 1, 21, 48 and 75 months for CD4 count, and at 6 weeks, 9, 36 and 66 months for 162 
CD8 count). Among patients with baseline CD4 count <200 cells/mm3, mean CD8 counts 163 
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increased steeply during the first 6 weeks of treatment, slowly decreased between 6 weeks 164 
and 9 months post-ART, slowly increased between 9 months and 3 years, and slowly 165 
decreased between 3 and 6 years. For example, among patients with baseline CD4 count <25 166 
cells/mm3 the estimated ratios of geometric mean CD8 count per month were 1.6724 [95% 167 
confidence interval 1.6509,1.6938] during the first 6 weeks of treatment, 0.9971 168 
[0.9948,0.9994] between 6 weeks and 9 months post-ART, 1.0045 [1.0038,1.0051] between 169 
9 months and 3 years, and 0.9969 [0.9963,0.9975] between 3 and 6 years. Lower baseline 170 
CD4 count predicted larger declines in CD8 count between 3 and 6 years post-ART (see 171 
Appendix-table 1). Among patients with baseline CD4 count 200–499 cells/mm3, mean CD8 172 
counts slowly increased during the first 6 weeks, steeply decreased from 6 weeks to 9 months 173 
post-ART and then slowly decreased from 9 months post-ART. For example, among patients 174 
with baseline CD4 count 200-349 cells/mm3, the estimated ratios of geometric mean CD8 175 
count per month were 1.0076 [1.0022,1.0130] during the first 6 weeks, 0.9805 176 
[0.9795,0.9814] between 6 weeks and 9 months, 0.9988 [0.9985,0.9991] between 9 months 177 
and 3 years, 0.9993 [0.9991,0.9996] between 3 and 6 years, and 0.9989 [0.9986,0.9991] from 178 
6 years to end of follow-up. Among patients with baseline CD4 count 500 cells/mm3, mean 179 
CD8 counts steeply decreased during the first 9 months post-ART, levelled-off between 9 180 
months and 3 years, and then slowly decreased thereafter. From 6 years post-ART, mean 181 
CD8 count plateaued among patients with baseline CD4 count <50 cells/mm3, but continued 182 
decreasing among patients with baseline CD4 count ≥50 cells/mm3.   183 
 184 
Mean CD4 counts increased throughout follow-up, except for patients with baseline CD4 185 
count 350 cells/mm3 in whom mean CD4 counts plateaued or slowly decreased between 21 186 
months and 6 years post-ART. Among all patients, the mean CD4:CD8 ratio trajectory 187 
followed the same pattern as the mean CD4 count, indicating that changes in CD4:CD8 ratio 188 
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were mainly driven by changes in CD4 count. However, during periods of decreasing CD8 189 
count, relative increases in the mean CD4:CD8 ratio were higher than those of mean CD4 190 
count. Among patients with baseline CD4 count <50 cells/mm3, increases in mean CD4:CD8 191 
ratio 6 years post-ART were only driven by CD4 count increases, whilst among the 192 
remaining patients increases in the mean CD4:CD8 ratio were driven by both increasing CD4 193 
counts and decreasing CD8 counts. During the 15-year follow-up period, the mean CD4:CD8 194 
ratio only exceeded 1 among patients with baseline CD4 count 200 cells/mm3: higher 195 
baseline CD4 count predicted a shorter time to mean CD4:CD8 ratio>1. 196 
 197 
Trends in mean CD8 count and CD4:CD8 ratio were similar between patients who were and 198 
were not virologically suppressed from 6 months post-ART (appendix-tables 2 and 3). 199 
However, changes in mean CD8 counts were more beneficial (smaller mean increases and 200 
larger mean decreases), and increases in the mean CD4:CD8 ratio were larger, among 201 
virologically suppressed patients compared to those not suppressed. 202 
 203 
Trends in mean CD4 counts, CD8 counts and CD4:CD8 ratio were similar among patients 204 
who started treatment before 2004 and those who started 2004 onwards. However, patients 205 
starting treatment from 2004 onwards had higher mean CD4 counts, lower mean CD8 counts 206 
and higher CD4:CD8 ratios throughout follow-up (results not shown). Including the 6% of 207 
patients who did not have any CD4 or CD8 measurements 6 months post-ART had minimal 208 
effect on the results (results not shown). 209 
  210 
Discussion 211 
Using data from a large collaborative study of HIV-infected individuals residing in Europe 212 
and North America, we found among patients with baseline CD4 count ≥50 cells/mm3, 213 
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predicted mean CD8 counts continued to decrease between 3 and 15 years post-ART, partly 214 
driving increases in the predicted mean CD4:CD8 ratio. Lower baseline CD4 count predicted 215 
higher increases in the mean CD4:CD8 ratio during the first 6 years since start of ART. 216 
Nonetheless, even 15 years since start of ART, the mean CD4:CD8 ratio did not normalise 217 
among patients with baseline CD4 count <200 cells/mm3. 218 
 219 
Few studies have reported long-term trends in post-ART CD8 counts. Two years post-ART, 220 
two studies reported similar findings to ours, of continued declines in CD8 counts [18;21], 221 
whilst three studies reported stabilised CD8 counts at elevated levels (approximately 600 to 222 
900 cells/mm3) [12;17;19]. However, sample sizes in these studies were small compared to 223 
ours (1253) and the patient populations heterogenous, consisting of late presenters or a 224 
mixture of treatment naïve and treatment experienced patients.   225 
 226 
Our findings regarding the CD4:CD8 ratio were similar to published small or restricted 227 
studies [18-20;23,24;30;31]. Continued increases in the CD4:CD8 ratio for 8 to 15 years 228 
since start of treatment have been reported among patients with sustained undetectable viral 229 
loads [18;20;23]. Among patients with baseline CD4 counts >350 cells/mm3, increases in the 230 
CD4:CD8 ratio were partly attributed to decreases in CD8 counts [18-20]. In one study 231 
examining CD4:CD8 ratio trends by baseline CD4 count, lower baseline CD4 count predicted 232 
higher increases during the first 5 years after start of ART [18]. Higher baseline CD4 count 233 
predicted faster time to normalised CD4:CD8 ratio [30] and a greater likelihood of attaining a 234 
normalised ratio [18;24;30,31]. 235 
 236 
In conclusion, there are long-term decreases in CD8 counts and long-term increases in 237 
CD4:CD8 ratios, among patients who start ART with CD4 count as low as 50-199 cells/mm3. 238 
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However, starting ART at high CD4 counts is paramount for attainment of a maximal 239 
CD4:CD8 ratio. 240 
 241 
Acknowledgements 242 
Rachael Hughes was supported by Medical Research Council grant [MR/J013773/1]. 243 
Jonathan Sterne was supported by grant number MR/J002380/1: this award was jointly 244 
funded by the UK Medical Research Council (MRC) and the UK Department for 245 
International Development (DFID) under the MRC/DFID Concordat agreement and is also 246 
part of the EDCTP2 programme supported by the European Union. He was also supported by 247 
National Institute for Health Research Senior Investigator award NF-SI-0611-10168. Viviane 248 
Lima is funded by a grant from the Canadian Institutes of Health Research (PJT-148595), by 249 
a Scholar Award from the Michael Smith Foundation for Health Research and a New 250 
Investigator award from the Canadian Institutes of Health Research.  251 
 252 
Conflicts of interest 253 
Dr. Costagliola reports potential conflicts of interest that are outside the submitted work. 254 
Grants from Janssen-Cilag (2014), Merck-Sharp & Dohme-Chibret (2017), ViiV (2015), 255 
personal fees from Janssen-Cilag (2016), Merck-Sharp & Dohme-Chibret (2015) for lectures, 256 
personal fees from Gilead (2014), ViiV (2015), Janssen-Cilag (2014) for 257 
travel/accommodations/meeting expenses, personal fees from Gilead France from 2011 until 258 
December 2015 for French HIV board, personal fees from Innavirvax (2015 and 2016), and 259 
Merck Switzerland (2017) for consultancy.  260 
Remaining authors report no potential conflicts.   261 
12 
 
12 
 
References 262 
[1] The Antiretroviral Therapy Cohort Collaboration. Survival of HIV-positive patients 263 
starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort 264 
studies. Lancet 2017;4:e349–e356. 265 
[2] Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS 266 
related morbidity. BMJ 2009;338:a3172. 267 
[3] Guaraldi G, Zona S, Alexopoulos N, Orlando G, Carli F, Ligabue G, et al. Coronary aging 268 
in HIV-infected patients. Clin Infect Dis 2009;49:1756–1762. 269 
[4] Hsue PY, Hunt PW, Schnell A, Kalapus SC, Hoh R, Ganz P, et al. Role of viral 270 
replication, antiretroviral therapy, and immunodeficiency in HIV-associated 271 
atherosclerosis. AIDS 2009;23:1059–1067. 272 
[5] Seaberg EC, Munoz A, Lu M, Detels R, Margolick JB, Riddler SA, et al. Association 273 
between highly active antiretroviral therapy and hypertension in a large cohort of men 274 
followed from 1984to 2003. AIDS 2005;19:953–960. 275 
[6] Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, et al. Antiretroviral 276 
therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS 277 
cohort study. Archives of Internal Medicine 2005;165:1179–1184.  278 
[7] Odden MC, Scherzer R, Bacchetti P, Szczech LA, Sidney S, Grunfeld C, et al. Cystatin C 279 
level as a marker of kidney function in human immunodeficiency virus infection: the 280 
FRAM study. Archives of Internal Medicine 2007; 167: 2213–2219. 281 
[8] Deeks S. HIV infection, inflammation, immunosenescence and aging. Annu Rev Med, 282 
2011; 62:141–155. 283 
[9] Appay V, Sauce D. Immune activation and inflammation in HIV infection: causes and 284 
consequences, J Pathol, 2008; 214: 231–241. 285 
13 
 
13 
 
[10] Ferguson FG, Wikby A, Maxson P, Olsson J, Johansson B. Immune parameters in a 286 
longitudinal study of a very old population of Swedish people: a comparison between 287 
survivors and nonsurvivors. J Gerontol A Biol Sci Med Sci, 1995, 50: B378–B382.  288 
[11] Wikby A, Maxson P, Olsson J, Johansson B, Ferguson FG (1998) Changes in CD8 and 289 
CD4 lymphocyte subsets, T cell proliferation responses and nonsurvival in the very old: 290 
the Swedish longitudinal OCTO-immune study. Mech Ageing Dev, 1998; 102: 187–198.  291 
[12] Lu W, Mehraj V, Vyboh K, Cao W, Li T, and Routy J-P. CD4:CD8 ratio as a frontier 292 
marker for clinical outcome, immune dysfunction and viral reservoir size in virologically 293 
suppressed HIV-positive patients. J Int AIDS Soc, 2015; 18:20052. 294 
[13] Trickey A, May MT, Schommers P, Tate J, Ingle SM, Guest JL, et al. CD4:CD8 Ratio 295 
and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus–296 
Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort 297 
Collaboration (ART-CC). Clin Infect Dis 2017; 65: 959–966. 298 
[14] Mocroft A, Phillips A, Gatell J, Ledergerber B, Fisher M, Clumeck N, et al. 299 
Normalisation of CD4 counts in patients with HIV infection and maximum virological 300 
suppression who are taking combination antiretroviral therapy: an observational cohort 301 
study. Lancet 2007; 370: 407–413.  302 
[15] Egger S, Petoumenos K, Kamarulzaman A, Hoy J, Sungkanuparph S, Chuah J, et al. 303 
Long-term patterns in CD4 response are determined by an interaction between baseline 304 
CD4 cell count, viral load, and time: The Asia Pacific HIV Observational Database 305 
(APHOD). J Acquir Immune Defic Syndr 2009; 50: 513–520. 306 
[16] Hughes RA, Sterne JAC, Walsh J, Bansi L, Gilson R, Orkin C, et al. Long-term trends in 307 
CD4 cell counts and impact of viral failure in individuals starting antiretroviral 308 
therapy:UK Collaborative HIV Cohort (CHIC) study. HIV Medicine, 2011; 12: 583–593. 309 
14 
 
14 
 
[17] Helleberg M, Kronborg G, Ullum H, Ryder LP, Obel N, Gerstoft J. Course and clinical 310 
significance of CD8+ T-cell counts in a large cohort of HIV-infected individuals. J Infect 311 
Dis, 2015; 211: 1726–1734. 312 
[18] Ndumbi P, Falutz J, Pant Pai N, Tsoukas CM. Delay in cART initiation results in 313 
persistent immune dysregulation and poor recovery of T-cell phenotype despite a decade 314 
of successful HIV suppression. PLoS One. 2014;9(4):e94018. 315 
[19] Serrano-Villar S, Sainz T, Lee SA, Hunt PW, Sinclair E, Shacklett BL, et al. HIV-316 
infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy 317 
exhibit altered T cell subsets, heightened CD8_T cell activation, and increased risk of non-318 
AIDS morbidity and mortality. PLoS Pathog. 2014;10:e1004078. 319 
[20] Cao W, Mehraj V, Trottier B, Baril J-G, Leblanc R, Lebouche B et al. Early initiation 320 
rather than prolonged duration of antiretroviral therapy in HIV infection contributes to the 321 
normalization of CD8+T-cell counts. Clin Infect Dis, 2016: 250-257.  322 
[21] Karo B, Krause G, Castell S, Kollan C, Hamouda O, Haas W, et al. Immunological 323 
recovery in tuberculosis/HIV co-infected patients on antiretroviral therapy: implication for 324 
tuberculosis preventive therapy. BMC Infectious Diseases, 2017; 17: 517. 325 
[22] Emu B, Moretto WJ, Hoh R, Krone M, Martin JN, Nixon DF, et al. Composition and 326 
Function of T Cell Subpopulations Are Slow to Change Despite Effective Antiretroviral 327 
Treatment of HIV Disease. Plos One, 2014; 9: e85613. 328 
[23] Saracino A, Bruno G, Scudeller L, Volpe A, Caricato P, Ladisa N, et al. Chronic 329 
Inflammation in a Long-Term Cohort of HIV-Infected Patients According to the 330 
Normalization of the CD4:CD8 Ratio. AIDS Research and Human Retroviruses, 2014; 30: 331 
1178-1184.  332 
15 
 
15 
 
[24] Caby F, writing committee of the CD4+/CD8+ Ratio Working Group of the French 333 
Hospital Database on HIV (FHDH-ANRS CO4). CD4+/CD8+ ratio restoration in long-334 
term treated HIV-1-infected individual. AIDS 2017, 31:1685–1695. 335 
 336 
[25] Serrano-Villar S, Perez-Elias MJ, Dronda F, Casado JL, Moreno A, Royuela A, et al. 337 
Increased risk of serious non-AIDS-related events in HIV-infected subjects on 338 
antiretroviral therapy associated with a low CD4/CD8 ratio. PLoS One. 2014;9:85798. 339 
[26] May MT, Ingle SM, Costagliola D, Justice AC, de Wolf F, Cavassini M, et al. Cohort 340 
profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). Int J 341 
Epidemiol 2014; 43:691–702. 342 
[27] StataCorp. 2015. Stata Statistical Software: Release 14. College Station, TX: StataCorp 343 
LP.  344 
[28] Leckie, G. and Charlton, C. runmlwin - A Program to Run the MLwiN Multilevel 345 
Modelling Software from within Stata. J Stat Softw, 52 (11),1-40.  346 
[29] Rasbash, J., Charlton, C., Browne, W.J., Healy, M. and Cameron, B. MLwiN Version 347 
2.1.  Centre for Multilevel Modelling, University of Bristol, 2009. 348 
[30] Leung V, Gillis J, Raboud J, Cooper C, Hogg RS, Loutfy MR, et al. Predictors of 349 
CD4:CD8 Ratio Normalization and Its Effect on Health Outcomes in the Era of 350 
Combination Antiretroviral Therapy. Plos One, 2013; 8: e77665. 351 
[31] Mussini C, Lorenzini P, Cozzi-Lepri A, Lapadula G, Marchetti G, Nicastri E, et al. 352 
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who 353 
achieve viral load suppression with antiretroviral therapy: an observational cohort study. 354 
Lancet HIV. 2015;2(3):e98–e106. 355 
16 
 
16 
 
Table 1.   Characteristics of the 39,979 patients eligible for analysis 
 Pre-treatment CD4 count (cells/mm3) 
 <25 25-49 50-99 100-199 200-349 350-499 500 
Number of participants 2510 1779 3018 7455 14141 6593 4483 
        
Median (IQR)a age (years) 38 (12) 40 (13) 39 (14) 39 (14) 38 (14) 38 (14) 37 (15) 
Male % 76 75 73 70 72 73 70 
Route of HIV infection   %        
   Homo/bisexual 27 31 33 34 41 45 43 
   IDU 11  11  11  11  9  9  9 
   Heterosexual 51 46 45 44 41 37 37 
   Other/not known 11  12  11  10  9  10  11 
Median (IQR)a baseline viral load (log10 
copies/ml) 
5.30  
(0.79) 
5.31  
(0.81) 
5.14  
(0.85) 
4.91  
(0.94) 
4.65  
(1.00) 
4.49  
(1.35) 
4.01  
(2.57) 
Median (IQR)a baseline CD8 (cells/mm3) 340 
 (320) 
480  
(421) 
610  
(501) 
749  
(540) 
900  
(594) 
981 
(674) 
1062 
(715) 
Median (IQR)a follow-up (months) 64  
(78) 
64  
(78) 
61  
(74) 
62  
(66) 
50  
(59) 
41  
(69) 
47  
(81) 
a IQR: Inter-quartile range 
